AOAC SPIFAN Stakeholder Program Meeting Book (September 10, 2020)

Background information

Compositionof human milk

•

Complex mixture of oligosaccharides

Lactose (68g/L)

• >200 HMO detected and ~160 HMO identified • Quantitative data available for ~30 HMO • Limited number of HMOs available in large scale ¾ 2’-FL; 3-FL; DFL ¾ LNnT; LNT ¾ 3’-SL; 6’-SL • Commercially available Infant formula (IF) fortified with: ¾ 2’-FL & LNnT • No certified reference materials of IF/ADN are available

Protein(10g/L)

Fat(39 g/L)

O S (13 g/L)

3

Background information Why quantifying HMO in Infant Formula? • R & D and product development • Confirmation of HMO level for safety trials, stability testing, efficacy trials, regulatory purposes • Quality control purposes to assure labeling compliance

Are there methods available? • Methods developed for (academic) HMO analysis in milk could be applied

• Small number of methods involving IF reported in literature • Methods not aligned as no official method is available

4